Bristol Myers Squibb Bolsters Oncology Pipeline with Lonza Licensing Agreement
Bristol Myers Squibb licenses Lonza's SYNtecan linker-payload platform to advance an undisclosed ADC target, with Lonza eligible for upfront payments, milestones and royalties on resulting products.
Lonza, a global contract development and manufacturing organization (CDMO), and Bristol Myers Squibb, a global pharmaceutical company, recently announced an exclusive single-target licensing agreement.
Under the terms of this agreement, BMS will gain exclusive access to the SYNtecan linker-payload platform to advance an ADC against an undisclosed target.
BMS will perform the research, development, manufacturing, and commercialization of the ADC. Lonza, through one of its affiliated companies, will be eligible to receive upfront, potential milestone payments, and royalty payments on net sales of resulting products.
Jan Vertommen, Vice President of Commercial Development, Advanced Synthesis, Lonza, said: “BMS has long been at the forefront of innovation in our industry, and this agreement marks a significant achievement in our collaboration with BMS. Licensing SYNtecan linker-payloads, our TOPO1 inhibitor platform, to BMS provides another strong validation of its strength and its trustworthiness in delivering positive clinical outcomes. We are pleased to add BMS to our partnered pipeline, as we collaborate to advance therapies that provide meaningful treatments to individuals who are still facing a critical unmet medical need.” (cs)
